Navigation Links
Kornberg Associates Architects Selected to Develop Design for New Stanford University Imaging Center
Date:7/11/2009

MENLO PARK, Calif., June 29 /PRNewswire/ -- Kornberg Associates | Architects (www.kornberg.com) has been selected by Stanford University to design a new Cognitive & Neurobiological Imaging Center. Ken Kornberg, president and founder, made the announcement. The firm has worked with Stanford University since 1980 and has completed 20 projects over the past 30 years, one of which is the two-story, 32,000 square-foot office building for the Stanford Linear Accelerator. They are also working on the new three-story 35,000 square-foot Stanford Institute for Economic Policy Research (SIEPR).

The School of Humanities and Sciences (H&S) awards nearly 80 percent of Stanford undergraduate degrees and more than 40 percent of doctoral degrees at Stanford. The school has more than 500 faculty members, 28 departments, and 19 interdisciplinary degree programs, along with a number of non-degree granting programs and 20 research centers and teaching resources.

According to Kornberg, the project, scheduled for completion in Fall 2010, will locate a functional magnetic resonance imaging (MRI) device and a magnetoencephalography (MEG) unit among the Cognitive Neurobiological Imaging researchers in the Psychology Department.

The two sites provided for the new imaging facilities are located in Jordan Hall, a 19th century stone structure built as part of the original historic Stanford Quadrangle. Both sites are primarily interior spaces. The MEG will be located in interior space on the 4th floor and the MRI facility will be in the basement of the west wing. The MEG will be located in existing interior office space and requires the complete demolition and renovation of 1,160 ft2. The MRI facility will displace 3,200 ft(2)of mixed use space in the basement.

"Many of the Psychology Department research i
'/>"/>

SOURCE Kornberg Associates
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology news :

1. Roger Kornberg to present lecture at the Joint Biophysical Society/IUPAB Meeting
2. Stanley to Acquire Oberon Associates
3. Stanley to Acquire Oberon Associates
4. Synaptics SecurePad(TM) Selected as CES Innovations 2008 Design and Engineering Award Honoree
5. Rwandas Gishwati Forest selected as site for historic conservation project
6. 19 researchers selected as 2008 Leopold Leadership Fellows
7. Motorola Biometric Identification System Selected by West Virginia State Police
8. Motorola Biometric Identification System Selected by West Virginia State Police
9. Atmels FingerChip Biometric Sensor Selected by Rise Computer for its Robust Security
10. M2SYS Technology Selected by ZOLL Data Systems to Integrate Fingerprint Software
11. M2SYS Technology Selected by TimeForge to Integrate Fingerprint Software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)...  23andMe, Inc., the leading personal genetics company, today ... differences in genetic ancestry of individuals from across ... immigrants first arrived more than four hundred years ago, ... as a meeting place for peoples from different continents. ... mixing of peoples with African, European, and American origins ...
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Practices (GCP) audit to confirm its adherence to ... This accomplishment enables HITLAB to conduct regulated smart ... highest principles for patient safety and research quality. ... healthcare access, quality, and delivery with innovative technology," ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... addition of the "Global Facial Recognition Market ... http://photos.prnewswire.com/prnh/20130307/600769 Facial ... of individuals. Facial recognition system measures the overall ... jaw edges, mouth, and the distance between eyes. ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... “cautionary tale?about what may go wrong when using the fledgling ... , In the February 16 issue of the Journal of ... M. D. Anderson Cancer Center detail why an experimental test ... of blood is unlikely to lead to a reliable clinical ...
... what may go wrong when using the fledgling science of ... the February 16 issue of the Journal of the National ... Anderson Cancer Center detail why an experimental test intended to ... is unlikely to lead to a reliable clinical test right ...
... of,HIV infection per act of heterosexual sex among a ... have more,than twice the risk of acquiring HIV than ... 15 issue of The Journal of,Infectious Diseases, now available ... Kenya collected detailed sexual data from a,group of male ...
Cached Biology News:Signaling protein builds bigger, better bones in mice 2Signaling protein builds bigger, better bones in mice 3New species from old data 2New species from old data 3Male circumcision reduces risk of HIV transmission from women to men 2
(Date:12/19/2014)... BioPlus Specialty Pharmacy ... has an expanded team of Regional Pharmaceutical Care ... prescriber offices in their regions, with specific areas ... a variety of Regional Pharmaceutical Care Liaisons specializing ... hepatitis C help prescribers understand all the new ...
(Date:12/19/2014)... Reports from CDC show ... from one or more chronic health conditions - including ... address some of these diseases, but may not eliminate ... face. While implanted nerve stimulation devices today offer relief, ... which can induce side effects. , To eliminate ...
(Date:12/19/2014)... December 18, 2014 With only 2 ... special on Sartorius Biohit products . The product ... pipettes, Picus Electronic Pipette Trade-in Program, and free pipette ... Safety officers around the world. They are ideal for ... features include:, ,     Full volume range of ...
(Date:12/19/2014)... 18, 2014 Relmada Therapeutics, Inc. (OTCQB: RLMD), ... of chronic pain, announced the results of its annual ... was a transformational year in Relmada,s history and it ... company," said Sergio Traversa , chief executive officer ... on key financial, human resource and clinical development objectives ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2
... MINNEAPOLIS, Aug. 24, 2011 Cellectis bioresearch, the ... Cellectis (Alternext: ALCLS), and Recombinetics, a specialist in ... development and license agreement on the creation of ... accordance with biosafety and animal well-being requirements, large ...
... Pa., Aug. 24, 2011 Kibow Biotech, Inc. today ... and marketing agreement with the current licensing partner specializing ... 100% natural, probiotic dietary supplement indicated for the reduction ... severe renal failure. Developed by Kibow, Azodyl™ has been ...
... SPRING, Md., Aug. 24, 2011 United Therapeutics ... the completion of its FREEDOM-C(2) Phase 3 trial ... release oral formulation of treprostinil, a stable synthetic ... hypertension (PAH).  Preliminary analysis demonstrates that the trial ...
Cached Biology Technology:Cellectis bioresearch Grants Recombinetics an Exclusive License Agreement for the Use of Targeted Nucleases in Large Livestock 2Cellectis bioresearch Grants Recombinetics an Exclusive License Agreement for the Use of Targeted Nucleases in Large Livestock 3Kibow Biotech, Inc. Secures $2.4 Million Towards Its Human Clinical Trials by Continued Veterinary Licensing Agreement 2FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint 2FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint 3FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint 4